Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celecoxib to decrease urinary retention associated with prostate brachytherapy.

Steven J Feigenberg1, Kellie L Wolk, Chin-Huey Yang

  • 1Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Brachytherapy
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.

International journal of particle therapy·2026
Same author

A Systematic Study on Local Failure Events Post Chemoradiation Therapy for Cervical Cancer: Understanding the Impact of Baseline Lateral Anatomic Compartment Involvement.

International journal of radiation oncology, biology, physics·2025
Same author

Pattern of recurrence with 1.0 cm CTV in brain glioblastoma treated with radiotherapy.

Journal of neuro-oncology·2025
Same author

Association Between Brain Substructure Dose and Scholastic Performance in Pediatric Brain Tumor Survivors Who Received Radiation Therapy.

International journal of radiation oncology, biology, physics·2025
Same author

Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies.

International journal of particle therapy·2025
Same journal

EM-tracked MR-US live fusion and needle location in gynecologic brachytherapy.

Brachytherapy·2026
Same journal

Contour and dosimetric evaluation of an in-room mobile CBCT scanner for cylinder based brachytherapy.

Brachytherapy·2026
Same journal

Brachytherapy for rectal cancer: An overview of clinical competency development in contemporary practice.

Brachytherapy·2026
Same journal

Deep learning-based automatic segmentation of rectal tumors in endoscopic images.

Brachytherapy·2026
Same journal

Online educational program for CT-based image-guided adaptive brachytherapy in cervical cancer: The BrachyAcademy experience.

Brachytherapy·2026
Same journal

On the surface of excellence: Core competencies for successful skin and superficial brachytherapy.

Brachytherapy·2026
See all related articles

Celecoxib use significantly reduced urinary retention after prostate brachytherapy. Patients receiving celecoxib experienced fewer catheter replacements and clinic visits, indicating improved outcomes.

Area of Science:

  • Urology
  • Oncology
  • Pharmacology

Background:

  • Prostate brachytherapy is a common treatment for localized prostate cancer.
  • Urinary retention is a frequent complication following prostate brachytherapy.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) have been explored for managing post-procedural complications.

Purpose of the Study:

  • To assess the efficacy of celecoxib in preventing acute urinary retention after prostate brachytherapy.
  • To evaluate the impact of celecoxib on the need for urinary catheterization and associated healthcare utilization.

Main Methods:

  • Retrospective review of medical records for 149 patients who underwent prostate brachytherapy between December 1997 and November 2001.
  • Urinary retention was quantified by catheter replacement and unscheduled clinic visits within one month post-procedure.

Related Experiment Videos

  • Comparison of outcomes between patients who received celecoxib and those who did not.

    • Main Results:

    • Celecoxib use was linked to a statistically significant decrease in catheter replacement (p=0.04).
    • Patients taking celecoxib showed a significant reduction in clinic calls and unscheduled visits (p=0.002).
    • None of the patients who received celecoxib for one week prior to brachytherapy required a urinary catheter, versus 14 out of 120 in the control group.

    Conclusions:

    • Celecoxib appears to be effective in reducing the incidence and severity of urinary retention post-prostate brachytherapy.
    • The findings suggest celecoxib may improve patient recovery and reduce healthcare resource utilization after the procedure.